Results 91 to 100 of about 1,349,663 (338)

Cost of clinical events in health economic evaluations in Germany: a systematic review

Cost Effectiveness and Resource Allocation, 2012
Guidance from the Institute for Quality and Efficiency in Health Care (IQWiG) on cost estimation in cost–benefit assessments in Germany acknowledges the need for standardization of costing methodology.
Scheuringer Monika, Sahakyan Narine, Krobot Karl J, Ulrich Volker   +3 more
doaj   +1 more source

Some reflections on the use of inappropriate comparators in CEA

Cost Effectiveness and Resource Allocation, 2020
Although the choice of the comparator is one of the aspects with a highest effect on the results of cost-effectiveness analyses, it is one of the less debated issues in international methodological guidelines. The inclusion of an inappropriate comparator
José Antonio Sacristán, José-María Abellán-Perpiñán, Tatiana Dilla, Javier Soto, Juan Oliva   +4 more
doaj   +1 more source

Cost-effectiveness of direct discharge from the emergency department of patients with simple stable injuries in the Netherlands [PDF]

, 2021
Thijs H. Geerdink, Niek Geerdink, Johanna M. van Dongen, Robert Haverlag, J. Carel Goslings, Ruben N. van Veen   +5 more
openalex   +1 more source

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

Molecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz, Anna L. Bartkowiak, Michael Rose, Nora Kolks, Patrick Petzsch, Vandana Solanki, Anne Stoffel, Bianca Faßbender, Leandra Lepping, Julka Volkamer, Karl Köhrer, Marc Seifert, Tokameh Mahmoudi, Tahlita C. M. Zuiverloon, Günter Niegisch, Michèle J. Hoffmann   +15 more
wiley   +1 more source

Incorporating MCDA into HTA: challenges and potential solutions, with a focus on lower income settings

Cost Effectiveness and Resource Allocation, 2018
Background Multicriteria decision analysis (MCDA) has the potential to bring more structure and transparency to health technology assessment (HTA). The objective of this paper is to highlight key methodological and practical challenges facing the use of ...
Kevin Marsh, Praveen Thokala, Sitaporn Youngkong, Kalipso Chalkidou   +3 more
doaj   +1 more source

Establishing cost-effectiveness of genetic targeting of cancer therapies [PDF]

, 2011
The clinical benefit of a new genomic instrument, the 70-gene signature for breast cancer patients, is being evaluated in a randomised clinical trial. The early, controlled implementation process is supported by a Constructive Technology Assessment to ...
Harten, W.H. van, Joore, M.A., Retèl, Valesca P., Rutgers, E.J.Th.   +3 more
core   +1 more source

Cis‐regulatory and long noncoding RNA alterations in breast cancer – current insights, biomarker utility, and the critical need for functional validation

Molecular Oncology, EarlyView.
The noncoding region of the genome plays a key role in regulating gene expression, and mutations within these regions are capable of altering it. Researchers have identified multiple functional noncoding mutations associated with increased cancer risk in the genome of breast cancer patients.
Arnau Cuy Saqués, Aracele Martinez‐Mendez, John Crown, Alex Eustace   +3 more
wiley   +1 more source

National cost study versus hospital cost accounting for organ recovery cost assessment in a French hospital group

Cost Effectiveness and Resource Allocation, 2018
Background The choice of cost data sources is crucial, because it influences the results of cost studies, decisions of hospital managers and ultimately national directives of policy makers.
Abdelbaste Hrifach, Christell Ganne, Sandrine Couray-Targe, Coralie Brault, Pascale Guerre, Hassan Serrier, Hugo Rabier, Gwen Grguric, Pierre Farge, Cyrille Colin   +9 more
doaj   +1 more source

The Cost-Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine in Seven Chinese Cities [PDF]

, 2021
Yan Li, Huaqing Wang, Wesley Furnback, Bruce C. M. Wang, Shuiqing Zhu, Peng Dong   +5 more
openalex   +1 more source

Methylation biomarkers can distinguish pleural mesothelioma from healthy pleura and other pleural pathologies

Molecular Oncology, EarlyView.
We developed and validated a DNA methylation–based biomarker panel to distinguish pleural mesothelioma from other pleural conditions. Using the IMPRESS technology, we translated this panel into a clinically applicable assay. The resulting two classifier models demonstrated excellent performance, achieving high AUC values and strong diagnostic accuracy.
Janah Vandenhoeck, Nele De Meulenaere, Thomas Vanpoucke, Joe Ibrahim, Dieter Peeters, Suresh Krishan Yogeswaran, Wen Wen, Paul Van Schil, Jeroen M. H. Hendriks, Jo Raskin, Jan van Meerbeeck, Guy Van Camp, Ken Op de Beeck   +12 more
wiley   +1 more source